Beneficial effects of oral magnesium supplementation on insulin sensitivity and serum lipid profile

Medical Science Monitor

Volumn 16, Issue 6, 2010, Pages

  Hadjistavri, Lina S ^a   Sarafidis, Pantelis A ^a   Georgianos, Panagiotis I ^a   Tziolas, Ioannis M ^a   Aroditis, Costas P ^a   Hitoglou Makedou, Areti ^a   Zebekakis, Pantelis E ^a   Pikilidou, Maria I ^a   Lasaridis, Anastasios N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

HOMA IR; Insulin sensitivity; Magnesium supplementation; Serum lipids

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYROGLUTAMATE MAGNESIUM; TRIACYLGLYCEROL; MAGNESIUM;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LABORATORY TEST; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MALE; ORAL GLUCOSE TOLERANCE TEST; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK;

ADMINISTRATION, ORAL; ADULT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIPIDS; MAGNESIUM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK;

EID: 80054049690     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Sarafidis PA, Nilsson PM: The metabolic syndrome: a glance at its history. J Hypertens, 2006; 24: 621-626
2. Sarafidis PA, Lasaridis AN: Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens, 2006; 19: 646-653
3. Barbagallo M, Dominguez LJ, Resnick LM: Magnesium metabolism in hypertension and type 2 diabetes mellitus. Am J Ther, 2007; 14: 375-385
4. Barbagallo M, Dominguez LJ: Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys, 2007; 458: 40-47
5. Lopez-Ridaura R, Willett WC, Rimm EB et al: Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care, 2004; 27: 134-140
6. He K, Liu K, Daviglus ML et al: Magnesium intake and incidence of metabolic syndrome among young adults. Circulation, 2006; 113: 1675-1682
7. He K, Song Y, Belin RJ et al: Magnesium intake and the metabolic syndrome: epidemiologic evidence to date. J Cardiometab Syndr, 2006; 1: 351-355
8. Balon TW, Jasman A, Scott S et al: Dietary magnesium prevents fructoseinduced insulin insensitivity in rats. Hypertension, 1994; 23: 1036-1039
9. Paolisso G, Sgambato S, Pizza G et al: Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care, 1989; 12: 265-269
10. Paolisso G, Scheen A, Cozzolino D et al: Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type II) diabetic patients. J Clin Endocrinol Metab, 1994; 78: 1510-1514
11. Rodriguez-Moran M, Guerrero-Romero F: Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care, 2003; 26: 1147-1152
12. Guerrero-Romero F, Tamez-Perez HE, Gonzalez-Gonzalez G et al: Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab, 2004; 30: 253-258
13. Bo S, Pisu E: Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes. Curr Opin Lipidol, 2008; 19: 50-56
14. Chobanian AV, Bakris GL, Black HR et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003; 289: 2560-2572
15. Mancia G, De Backer G, Dominiczak A et al: 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press, 2007; 16: 135-232
16. Stumvoll M, Van HT, Fritsche A et al: Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care, 2001; 24: 796-797
17. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care, 1999; 22: 1462-1470
18. Cederholm J, Wibell L: Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract, 1990; 10: 167-175
19. Soonthornpun S, Setasuban W, Thamprasit A et al: Novel insulin sensitivity index derived from oral glucose tolerance test. J Clin Endocrinol Metab, 2003; 88: 1019-1023
20. Purves RD: Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharmacokinet Biopharm, 1992; 20: 211-226
21. Bonora E, Targher G, Alberiche M et al: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care, 2000; 23: 57-63
22. Matthews DR, Hosker JP, Rudenski AS et al: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28: 412-419
23. Paolisso G, Sgambato S, Gambardella A et al: Daily magnesium supplements improve glucose handling in elderly subjects. Am J Clin Nutr, 1992; 55: 1161-1167
24. Mari A, Pacini G, Brazzale AR et al: Comparative evaluation of simple insuli sensitivity methods based on the oral glucose tolerance test. Diabetologia, 2005; 48: 748-751
25. Barbagallo M, Dominguez LJ, Galioto A et al: Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med, 2003; 24: 39-52
26. Resnick LM: Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of ''syndrome X''. Am J Hypertens, 1993; 6: 123S-134S
27. Barbagallo M, Gupta RK, Bardicef O et al: Altere d ionic effects of insulinin hypertension: role of basal ion levels in determining cellular responsiveness. J Clin Endocrinol Metab, 1997; 82: 1761-1165
28. Rosolova H, Mayer O, Reaven GM: Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrations. Metabolism, 2000; 49: 418-420
29. Suarez A, Pulido N, Casla A et al: Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic rats. Diabetologia, 1995; 38: 1262-1270
30. Corica F, Allegra A, Di Benedetto A et al: Effects of oral magnesium supplementation on plasma lipid concentrations in patients with noninsulin- dependent diabetes mellitus. Magnes Res, 1994; 7: 43-47
31. Witteman JC, Grobbee DE, Derkx FH et al: Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension. Am J Clin Nutr, 1994; 60: 129-135
32. Song Y, He K, Levitan EB et al: Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med, 2006; 23: 1050-1056
33. Olatunji LA, Soladoye AO: Increased magnesium intake prevents hyperlipidemia and insulin resistance and reduces lipid peroxidation in fructose-fed rats. Pathophysiology, 2007; 14: 11-15